Published in Adv Cancer Res on January 01, 2001
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease | NCT00088374
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease | NCT00062166
Phase II Study of Vandetanib in Individuals With Kidney Cancer | NCT00566995
Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol (2003) 2.59
Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet (2003) 2.43
An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol (2009) 1.80
The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex. Mol Cell Biol (2003) 1.62
Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review. Retina (2007) 1.25
Oxygen-sensing mechanisms and the regulation of redox-responsive transcription factors in development and pathophysiology. Respir Res (2002) 0.97
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
Tubular deficiency of von Hippel-Lindau attenuates renal disease progression in anti-GBM glomerulonephritis. Am J Pathol (2011) 0.89
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Surgery (2011) 0.84
Functional Subunits of Eukaryotic Chaperonin CCT/TRiC in Protein Folding. J Amino Acids (2011) 0.84
Esophagogastric varices due to arterioportal shunt in a serous cystadenoma of the pancreas in von Hippel-Lindau disease. Dig Dis Sci (2003) 0.80
Development of lymphoproliferative diseases by hypoxia inducible factor-1alpha is associated with prolonged lymphocyte survival. PLoS One (2013) 0.79
A case of von Hippel-Lindau disease with exudative maculopathy. Oman J Ophthalmol (2009) 0.77
Single-stage laparoscopic adrenalectomy for pheochromocytoma and enucleation of a pancreatic neuroendocrine tumor in Von Hippel-Lindau disease: A case report. Mol Clin Oncol (2017) 0.75
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem (2000) 5.58
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet (2001) 4.71
A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. Proc Natl Acad Sci U S A (1999) 3.37
Use of prenatal chromosomal microarray: prospective cohort study and systematic review and meta-analysis. Ultrasound Obstet Gynecol (2013) 3.28
Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases. Clin Genet (1994) 3.04
Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat (1996) 2.80
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet (2006) 2.68
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet (2001) 2.56
Beckwith-Wiedemann syndrome and assisted reproduction technology (ART). J Med Genet (2003) 2.48
Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet (1999) 2.41
Familial gastric cancer: overview and guidelines for management. J Med Genet (1999) 2.38
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer (1998) 2.27
Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain. Hum Mol Genet (1995) 2.27
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22
Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res (2001) 2.12
Imprinting in clusters: lessons from Beckwith-Wiedemann syndrome. Trends Genet (1997) 2.01
Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer (2002) 1.95
The VHL tumour-suppressor gene paradigm. Trends Genet (1998) 1.94
Additional information from array comparative genomic hybridization technology over conventional karyotyping in prenatal diagnosis: a systematic review and meta-analysis. Ultrasound Obstet Gynecol (2011) 1.85
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA (1995) 1.83
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82
The genetics of paragangliomas: a review. Clin Otolaryngol (2007) 1.77
Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J Med Genet (1999) 1.74
Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene (2010) 1.69
Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome. J Med Genet (2003) 1.68
Beckwith-Wiedemann syndrome. J Med Genet (1994) 1.67
Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol (1999) 1.64
Germline SDHD mutation in familial phaeochromocytoma. Lancet (2001) 1.62
A genetic register for von Hippel-Lindau disease. J Med Genet (1996) 1.61
Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology (2008) 1.60
Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' APC gene mutation. Hum Mol Genet (1996) 1.57
Imprinting mutation in the Beckwith-Wiedemann syndrome leads to biallelic IGF2 expression through an H19-independent pathway. Hum Mol Genet (1996) 1.57
The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1986) 1.55
Imprinting of IGF2 and H19: lack of reciprocity in sporadic Beckwith-Wiedemann syndrome. Hum Mol Genet (1997) 1.54
Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet (1997) 1.54
Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene (2010) 1.52
Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. J Med Genet (2000) 1.51
Molecular genetic tests in surgical management of familial adenomatous polyposis. Lancet (1997) 1.50
Recurrent germline mutation in MSH2 arises frequently de novo. J Med Genet (2000) 1.49
Syntenic organization of the mouse distal chromosome 7 imprinting cluster and the Beckwith-Wiedemann syndrome region in chromosome 11p15.5. Hum Mol Genet (1998) 1.49
Assisted reproductive therapies and imprinting disorders--a preliminary British survey. Hum Reprod (2005) 1.48
Mapping of a novel locus for achromatopsia (ACHM4) to 1p and identification of a germline mutation in the alpha subunit of cone transducin (GNAT2). J Med Genet (2002) 1.44
Achromatopsia caused by novel mutations in both CNGA3 and CNGB3. J Med Genet (2004) 1.44
Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br J Cancer (2004) 1.42
Dialysis amyloid presenting as acute arthritis. Nephron (1988) 1.40
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer (2012) 1.39
Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer (2005) 1.39
Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res (2001) 1.35
The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene (2001) 1.34
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation. J Med Genet (2007) 1.30
Mosaic uniparental disomy in Beckwith-Wiedemann syndrome. J Med Genet (1994) 1.28
Atherosclerotic renovascular disease causing renal impairment--a case for treatment. Clin Nephrol (1989) 1.28
Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. J Med Genet (1995) 1.26
Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet (1995) 1.25
Epigenotype-phenotype correlations in Silver-Russell syndrome. J Med Genet (2010) 1.24
Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br J Cancer (2008) 1.23
Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet (1996) 1.23
Mononucleotide microsatellite instability and germline MSH6 mutation analysis in early onset colorectal cancer. J Med Genet (1999) 1.23
A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. J Med Genet (1999) 1.21
Epigenetic modification and uniparental inheritance of H19 in Beckwith-Wiedemann syndrome. J Med Genet (1997) 1.18
Molecular genetic analysis of von Hippel-Lindau disease. J Intern Med (1998) 1.17
Uptake of genetic testing for cancer predisposition. J Med Genet (1997) 1.16
Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet (1997) 1.15
Intrapericardial installation of bleomycin in malignant pericardial effusion. Am Heart J (1986) 1.14
SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Fam Cancer (2009) 1.14
Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas. Endocr Relat Cancer (2005) 1.14
RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene (2001) 1.12
Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br J Cancer (2001) 1.11
A locus for isolated cataract on human Xp. J Med Genet (2002) 1.11
Genetic linkage between von Hippel-Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus. Hum Mol Genet (1993) 1.10
Ophthalmological screening for von Hippel-Lindau disease. Eye (Lond) (1991) 1.10
SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma. Br J Cancer (2004) 1.10
Analysis of the Birt-Hogg-Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. J Med Genet (2003) 1.10
The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-kappaB signaling pathways. Oncogene (2010) 1.10
Allelic methylation of H19 and IGF2 in the Beckwith-Wiedemann syndrome. Hum Mol Genet (1994) 1.09
Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene (2010) 1.08
A locus for asphyxiating thoracic dystrophy, ATD, maps to chromosome 15q13. J Med Genet (2003) 1.08
An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genet (1998) 1.07
Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene (2007) 1.06
Detailed mapping of a congenital heart disease gene in chromosome 3p25. J Med Genet (2000) 1.05
A frequent hMSH2 mutation in hereditary non-polyposis colon cancer syndrome. Lancet (1995) 1.04
Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22. Br J Cancer (1994) 1.04
Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum Mol Genet (1994) 1.03
Microsatellite instability in early onset and familial colorectal cancer. J Med Genet (1996) 1.02
Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. Mol Pathol (2000) 1.02
Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res (1999) 1.02
Accumulation of aluminium in chronic renal failure due to administration of albumin replacement solutions. Br Med J (Clin Res Ed) (1986) 1.01
Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery (2000) 0.98
Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). J Neurol Neurosurg Psychiatry (1985) 0.98
Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J Clin Pathol (2004) 0.97
Cystic fibrosis diagnosed by molecular genetic investigation in the mother of a patient with cystic fibrosis. Thorax (1997) 0.97
Comparative sequence analysis of the VHL tumor suppressor gene. Genomics (2000) 0.97
Germline mutation in DOK7 associated with fetal akinesia deformation sequence. J Med Genet (2009) 0.96
Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma. Br J Cancer (2004) 0.96
Identification of a novel mutation disrupting the DNA binding activity of GCM2 in autosomal recessive familial isolated hypoparathyroidism. J Med Genet (2005) 0.95
Analysis of CRELD1 as a candidate 3p25 atrioventicular septal defect locus (AVSD2). Clin Genet (2005) 0.95
Identification of novel TYR and TYRP1 mutations in oculocutaneous albinism. Clin Genet (2005) 0.94
Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases. Hum Genet (2001) 0.94